Warning! OUTDATED BROWSER DETECTED!   Please update your browser immediately for a better experience on this website. Learn More
21/xsl/MobileMenu.xsltmobileNave880e1541/WorkArea//http://www.rsna.org/Content.aspx?id=14428&ekfxmen_noscript=1&ekfxmensel=falsefalsetruetruetruefalsefalse10-18.0.0.0730truefalse

Theodore S. Lawrence, MD, PhD

Theodore S. Lawrence, MD, PhD, has established himself as a world-renowned researcher for his pioneering use of radiation for the treatment of intrahepatic cancers. In particular, he led a team that developed a model that predicts the maximum safe dose of radiation that can be given to liver tumors, and showed that these higher doses could cure some previously incurable cancers.

More recently Dr Lawrence has been working with radiologists to develop new methods of imaging and then targeting resistant portions of liver tumors and avoiding sensitive regions of the normal liver. He also has led laboratory studies to optimize the use of chemotherapeutic radiosensitizers. His preclinical and clinical work established the combination gemcitabine and radiation as a standard therapy for pancreatic cancer. He is now focused on combining molecularly targeted radiation sensitizers with chemotherapy and radiation therapy.

Dr Lawrence is the chair of the Department of Radiation Oncology and the Isadore Lampe Professor of Radiation Oncology at the University of Michigan (Ann Arbor, Mich) and co-chair of the Radiation Sciences Program of the University of Michigan Comprehensive Cancer Center. He is president of the Radiation Oncology Institute and of the Society of Chairs of Radiation Oncology.

Dr Lawrence joined the faculty of the University of Michigan in 1987, following a fellowship in medical oncology and a residency in radiation oncology at the National Cancer Institute. He received his research degree in cell biology from the Rockefeller University (New York, NY), followed by his medical degree from Cornell University (New York, NY) and an internal medicine residency at Stanford University (Stanford, Calif).

Dr Lawrence is a member of the Board of Scientific Advisors of the National Cancer Institute and a member of the Institute of Medicine of the National Academy of Science. He is an editor of Translational Oncology and The Cancer Journal, a senior editor ofCancer Research, and an associate editor of Seminars in Radiation Oncology. He also served as associate editor at the Journal of the National Cancer InstituteRadiation Oncology InvestigationsRadiation ResearchCancer Therapeutics, and the Journal of Clinical Oncology.

In addition to the United States, Dr Lawrence has lectured in 10 countries on three continents (Asia, Australia, Europe). He presented the Annual Oration in Radiation Oncology, “Looking Beyond Anatomic-based Treatment in Radiation Oncology,” at RSNA 2006. Dr Lawrence, who has served on numerous international, national, and university committees has authored 267 studies appearing in peer-reviewed journals and 31 book chapters during his illustrious career.

Dr Lawrence is past-president of the American Society of Radiation Oncology (ASTRO), former chair of the National Cancer Institute Board of Scientific Councilors, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO). He has been honored with the ASTRO gold medal and an ASCO statesman award. RSNA is pleased to add Outstanding Researcher to Dr Lawrence’s accolades.